UZEDY® Exceeds Sales Expectations with $117M Revenue in First Full Year
Teva Pharmaceuticals' long-acting injectable antipsychotic UZEDY® has demonstrated strong market performance, generating $117 million in sales during its first full year of commercialization in 2024. The fourth quarter alone contributed $43 million to the total revenue, marking a 17% increase over Teva's revised November outlook of $100 million.
The successful market penetration has prompted Teva to set an ambitious sales target of $160 million for 2025, double their initial 2024 projection of $80 million. This growth trajectory signals strong market acceptance and expanding clinical adoption of the long-acting formulation.
Commercial Impact and Partnership Details
For MedinCell, the French biotechnology company behind UZEDY®'s formulation technology, the commercial success translates into significant revenue potential. The company is entitled to mid- to high-single digit royalties on all sales and stands to receive up to $105 million in commercial milestone payments.
Pipeline Development: Olanzapine Long-Acting Injectable
Building on this momentum, Teva and MedinCell are advancing their pipeline with TEV-749/mdc-TJK, a long-acting injectable formulation of olanzapine. The development program is reaching critical milestones, with the last patient visit in the Phase 3 pivotal trial expected imminently. The companies anticipate releasing long-term safety data in the second quarter of 2025, followed by a New Drug Application (NDA) submission to regulatory authorities in the second half of the year.
The advancement of the olanzapine program represents a significant opportunity to expand the partnership's presence in the long-acting injectable antipsychotic market, potentially addressing another significant unmet need in psychiatric care.